

Mycosis Fungoides

Stage IA-IIA

Cytotoxic Lymphoma

Systemic Therapy

Treatment Naive

No Prior Moga

Failed 1 Therapy

No Prior Moga or Moga Tx

Treatment

Failed 2 Therapies

LYMNHL0167
 Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
 PI Kim
 Sponsor: Dren Bio Inc.

LYMNHL0149
[Phase II Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis](#)
 PI: Kim
 Sponsor: Memorial Sloan Kettering

LYMNHL0164
[Phase II Mogamulizumab in Relapsed / Refractory Cutaneous T-Cell Lymphoma \(CTCL\)](#)
 PI: Kim
 Sponsor: Kyowa Hakko Kirin Pharma, Inc.

LYMNHL0155
[Phase II Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome](#) ♦
 PI: Kim
 Sponsor: Stanford University

LYMNHL0159
[Phase Ib/II Hu5F9-G4 \(Magrolimab\) +/- Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma](#)
 PI: Khodadoust
 Sponsor: CITN

LYMNHL0166
 FLASH-CL Feasibility Study Single-Fraction FLASH vs Conventional Electron Radiotherapy for Multilesional Primary Cutaneous Lymphomas
 PI: Dworkin
 Sponsor: Stanford University

KIR3DL2
LYMNHL0151
[Phase II IPH4102 +/- Chemotherapy in Advanced T-cell Lymphoma](#) ♦
 PI: Kim
 Sponsor: Innate Pharma

LYMNHL0153
[Phase 1/1b CPI-818\(Oral Interleukin-2-ITK Inhibitor\) in Relapsed/Refractory T-Cell Lymphoma](#)
 PI: Kim
 Sponsor: Corvus Pharmaceuticals, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study
- ♦ Immunotherapy